{"gene":"IGFBP2","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2010,"finding":"Adenoviral overexpression of IGFBP2 reversed diabetes in insulin-resistant ob/ob, Ay/a, diet-induced obese, and streptozotocin-treated mice; hyperinsulinemic clamp studies showed a 3-fold improvement in hepatic insulin sensitivity, establishing IGFBP2 as a regulator of glucose metabolism downstream of leptin signaling.","method":"Adenoviral overexpression in mouse models, hyperinsulinemic clamp studies, liver microarray profiling","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vivo methods (multiple mouse models + clamp studies), replicated across disease models","pmids":["20074524"],"is_preprint":false},{"year":2003,"finding":"IIp45, identified by yeast two-hybrid screening, binds to IGFBP2 through the thyroglobulin-RGD region of IGFBP2's C-terminus, and this interaction antagonizes IGFBP2-stimulated glioma cell invasion both in vitro and in xenograft models, partly by suppressing NF-κB and ICAM-1 expression.","method":"Yeast two-hybrid, co-immunoprecipitation, invasion assays, xenograft model, gene expression profiling","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding confirmed, functional rescue in vitro and in vivo, pathway placement via NF-κB","pmids":["14617774"],"is_preprint":false},{"year":2011,"finding":"IGFBP2 overexpression in neuroblastoma cells transactivates the VEGF gene promoter; cell fractionation and immunofluorescence demonstrated nuclear localization of IGFBP2, and transactivation of VEGF promoter required intracellular IGFBP2, leading to proangiogenic activity in chick chorioallantoic membrane xenografts.","method":"VEGF promoter luciferase reporter cotransfection, cell fractionation, immunofluorescence, CAM xenograft assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1–2 — promoter assay with functional rescue, subcellular fractionation, and in vivo angiogenesis assay in single study","pmids":["21750048"],"is_preprint":false},{"year":2015,"finding":"IGFBP2 binding to receptor tyrosine phosphatase β (RPTPβ) together with IGF-I receptor stimulation induces PKCζ-mediated vimentin serine phosphorylation, which drives RPTPβ polymerization, PTEN inactivation, and AKT activation to stimulate vascular smooth muscle cell proliferation during hyperglycemia.","method":"Proteomic co-immunoprecipitation, siRNA knockdown, cell-permeable inhibitory peptides, in vivo diabetic mouse model with pharmacological inhibitors","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — proteomic identification of binding partner, mechanistic validation with multiple inhibitors, confirmed in vivo in diabetic mice","pmids":["25787077"],"is_preprint":false},{"year":2015,"finding":"IGFBP2 augments nuclear accumulation of EGFR and potentiates EGFR-STAT3 signaling, promoting invasion and migration of glioblastoma cells; both exogenous IGFBP2 treatment and intracellular IGFBP2 overexpression activated this nuclear EGFR/STAT3 axis.","method":"Nuclear fractionation, invasion/migration assays, siRNA knockdown, TCGA data correlation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — nuclear fractionation and functional assays in single lab, pathway placement via EGFR/STAT3","pmids":["25893308"],"is_preprint":false},{"year":2016,"finding":"IGFBP2 drives NF-κB-dependent epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma by inducing nuclear translocation and phosphorylation of the p65 NF-κB subunit through the PI3K/Akt/IKKβ pathway; enforced PTEN expression blocked this pathway and restored epithelial phenotype.","method":"Overexpression/knockdown, invasion and metastasis assays in vitro and in vivo, immunofluorescence for p65 translocation, PTEN rescue experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with genetic rescue (PTEN), confirmed in vivo, mechanistic pathway placed","pmids":["27659045"],"is_preprint":false},{"year":2018,"finding":"IGFBP2 interacts with integrin α5 and β1 subunits, activating FAK/ERK signaling to increase SP1 transcriptional activity, which binds the CD144 promoter and upregulates CD144 and MMP2, thereby promoting vasculogenic mimicry formation in glioma cells.","method":"Co-immunoprecipitation (integrin interaction), luciferase reporter assay, ChIP assay, stable knockdown orthotopic mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 — binding partner confirmed by Co-IP, promoter binding by ChIP, in vivo confirmation in orthotopic model","pmids":["30368528"],"is_preprint":false},{"year":2015,"finding":"IGF-I and IGFBP-2 coordinately stimulate AMPK activation through their respective receptors in osteoblasts; early AMPK induction drives ULK-1 phosphorylation, beclin-1 and LC3II induction (autophagy), which is required for osteoblast differentiation, while sustained AMPK activation inhibits differentiation.","method":"Primary calvarial osteoblast culture, MC-3T3 cells, AMPK inhibitors, constitutively active AMPK expression, autophagy inhibitors, receptor-blocking antibodies","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological and genetic interventions with time-course analysis, receptor-level mechanistic dissection","pmids":["26556533"],"is_preprint":false},{"year":2008,"finding":"MMP-9 proteolytically cleaves the IGFBP2-IGFII complex in vitro, releasing free IGFII that enhances astrocytoma cell motility and growth; formation of the IGFBP2-IGFII complex also reduces the pool of free IGFBP2 and thereby inhibits IGFBP2's own cell motility-promoting effect.","method":"In vitro protease cleavage assay, cell motility and proliferation assays using LN229 cells, conditioned medium experiments","journal":"Glia","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro enzymatic cleavage assay with functional readout, mechanistic dissection of complex vs. free IGFBP2","pmids":["18563800"],"is_preprint":false},{"year":2013,"finding":"Exogenous IGFBP2 acting via integrin receptors reduces PTEN levels in breast epithelial cells, protecting them from apoptosis and conferring chemoresistance; this survival function requires functional estrogen receptor-α, and conversely IGFBP2 upregulates ER-α expression via integrin receptors through IGF-IR and PI3K activation in cancer cells.","method":"siRNA knockdown, exogenous IGFBP2 treatment, integrin receptor blocking, PI3K inhibitors, ER-α silencing, cell survival assays","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological perturbations with orthogonal readouts in single study","pmids":["23515291"],"is_preprint":false},{"year":2014,"finding":"IGFBP2 inhibits adipogenesis and lipogenesis specifically in visceral (not subcutaneous) human adipocytes via its heparin-binding domain mediating cell-surface association and integrin signaling, leading to FAK phosphorylation and decreased PTEN levels, independent of IGF-I.","method":"siRNA knockdown, exogenous IGFBP2 dose-response, HBD-mutant IGFBP2, echistatin (integrin blocker), Western blotting, lipid staining","journal":"International journal of obesity","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological methods with domain-specific mutant, depot-specific mechanistic dissection","pmids":["25370576"],"is_preprint":false},{"year":2013,"finding":"IGFBP2 is inhibitory to IGF1R phosphorylation and downstream signaling; in rhabdomyosarcoma, downregulation of IGFBP2 confers resistance to IGF1R antibody therapy, and adding exogenous IGFBP2 potentiates IGF1R antibody activity and reverses resistance in vitro and in vivo.","method":"In vivo resistance model, exogenous IGFBP2 supplementation, expression analysis, IGF1R phosphorylation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro causal evidence for IGFBP2's inhibitory role on IGF1R signaling, single lab","pmids":["24292683"],"is_preprint":false},{"year":2013,"finding":"Hyperglycemia induces IGFBP2 expression in prostate cancer cells via increased acetylation of histones H3 and H4 at the IGFBP2 gene promoter (epigenetic mechanism); elevated IGFBP2 reduces docetaxel-induced apoptosis, and silencing IGFBP2 negates the glucose-mediated survival advantage.","method":"siRNA knockdown, chromatin immunoprecipitation (ChIP) for histone acetylation, DNA methylation analysis, ELISA, cell death assay","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP demonstrates epigenetic writer mechanism, siRNA rescue confirms causality, single lab","pmids":["23959956"],"is_preprint":false},{"year":2016,"finding":"Intronic CpG methylation of IGFBP2 (CpG2605) suppresses its hepatic expression; selective methylation of this site in vitro reduced reporter activity by ~85%, and this epigenetic silencing precedes diet-induced obesity and hepatosteatosis in mice.","method":"Bisulfite sequencing, in vitro methylation reporter assay, mouse dietary model with epigenetic profiling","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — in vitro site-specific methylation with reporter assay, causal temporal relationship established in vivo","pmids":["27126637"],"is_preprint":false},{"year":2017,"finding":"MMP-1 cleaves the IGF-2/IGFBP2 complex, releasing free IGF-2 that facilitates mesenchymal stem cell migration toward tumors; conditioned media from highly migrating MSCs expressing high MMP-1 cleaved the IGF-2/IGFBP2 complex in vitro.","method":"In vitro cleavage assay with conditioned media, exogenous recombinant protein addition, migration assays","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 1–2 — direct in vitro cleavage assay, single lab, moderate mechanistic depth","pmids":["29321953"],"is_preprint":false},{"year":2018,"finding":"In salivary adenoid cystic carcinoma, IGFBP2 nuclear localization signal is required for nuclear translocation of NF-κB p65; nuclear IGFBP2 enhances p65-dependent ZEB1 expression to promote EMT; IGFBP2 NLS mutant failed to translocate p65, reduced ZEB1, and abrogated EMT and metastasis in xenograft models.","method":"IGFBP2 NLS mutant transfection, nuclear fractionation, invasion assays, xenograft metastasis model","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 2 — domain-specific mutagenesis with in vitro and in vivo validation, pathway placement via NF-κB/ZEB1","pmids":["29885520"],"is_preprint":false},{"year":2020,"finding":"IGFBP2 activates STAT3 in pancreatic ductal adenocarcinoma cells to augment IL-10 secretion, which drives tumor-associated macrophage polarization toward an M2 immunosuppressive phenotype, increasing Treg infiltration and impairing antitumor T-cell immunity.","method":"In vivo mouse model (macrophage depletion), STAT3 signaling analysis, IL-10 ELISA, flow cytometry for immune cell populations","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo macrophage-dependent validation and mechanistic STAT3/IL-10 link, single lab","pmids":["33309859"],"is_preprint":false},{"year":2020,"finding":"Intracellular IGFBP2 stabilizes cytoplasmic p21 by protecting it from ubiquitin-dependent degradation in psoriatic keratinocytes; cytoplasmic p21 in turn inhibits pro-caspase 3 cleavage and JNK phosphorylation to resist apoptosis; silencing IGFBP2 destabilizes p21 and restores apoptosis.","method":"IGFBP2 overexpression/silencing in psoriatic keratinocytes, co-immunoprecipitation (IGFBP2-p21 interaction), ubiquitin-mediated degradation assays, caspase and JNK activity assays","journal":"Aging","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of endogenous interaction, functional rescue with multiple downstream readouts, mechanistically distinct intracellular role defined","pmids":["32302288"],"is_preprint":false},{"year":2020,"finding":"IGFBP2 regulates PD-L1 expression in melanoma by facilitating nuclear accumulation of EGFR and activating the EGFR/STAT3 signaling pathway, confirmed both in vitro and in vivo.","method":"IGFBP2 knockdown/overexpression, nuclear EGFR fractionation, STAT3 phosphorylation assays, in vivo melanoma models","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — nuclear EGFR mechanism consistent with prior IGFBP2/EGFR/STAT3 papers, single lab, mechanistic readouts","pmids":["32120023"],"is_preprint":false},{"year":2020,"finding":"IGFBP2 in glioblastoma cells induces TRIM33 (an E3 ubiquitin ligase) expression via integrin signaling, which depletes nuclear β-catenin; simultaneously, IGFBP2-stabilized cytoplasmic β-catenin binds the 3' UTR of Oct4 RNA, enhancing stemness of glioma cells.","method":"RT-PCR, Western blot, shRNA knockdown, RNA immunoprecipitation (RNAIP), luciferase reporter, neurosphere assay","journal":"Journal of neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 — RNA-protein interaction confirmed by RNAIP, mechanistic pathway defined, single lab","pmids":["32803659"],"is_preprint":false},{"year":2017,"finding":"IGFBP2 exerts anxiolytic and antistress effects in rat PTSD models via an IGF-1 receptor-independent mechanism (not blocked by IGF1R antagonist JB1 or AMPA receptor antagonist NBQX); IGFBP2 increases mature dendritic spine density in medial prefrontal cortex and hippocampus 24 hours post-dosing, suggesting structural plasticity as the underlying mechanism.","method":"Porsolt test, contextual fear conditioning, chronic unpredictable stress model; selective receptor antagonists; dendritic spine morphology analysis in vivo","journal":"The international journal of neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection of IGF1R-independence with multiple behavioral models, in vivo structural readout, single lab","pmids":["28158790"],"is_preprint":false},{"year":2005,"finding":"IGFBP2 overexpression in chick embryo wing by RCAS retroviral vector inhibits IGF-I and IGF-II-mediated chondrocyte proliferation and matrix synthesis, resulting in shortened long bones; IGFBP2 excess also attenuates perichondrium/periosteum proliferation without affecting markers of chondrocyte maturation or osteoblast differentiation.","method":"RCAS retroviral overexpression in embryonic chick wing, in vivo skeletal morphometry, in vitro chondrocyte proliferation/matrix synthesis assays with IGF-I/II","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 — in vivo and in vitro mechanistic dissection, multiple cellular readouts, defined pathway (inhibition of IGF-mediated proliferation)","pmids":["16183342"],"is_preprint":false},{"year":2012,"finding":"MDA-9/syntenin induces HIF-1α via ECM-Src-FAK-Akt signaling, which activates transcription of IGFBP2; secreted IGFBP2 promotes tumor angiogenesis and stimulates endothelial cells to produce and secrete VEGF-A.","method":"Gain/loss-of-function experiments, tube formation assay, CAM assay, xenograft tumor model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic manipulation with in vitro and in vivo angiogenesis assays, pathway placed downstream of HIF-1α, single lab","pmids":["23233738"],"is_preprint":false},{"year":2023,"finding":"Loss of IGFBP2 in alveolar type 2 (AEC2) cells promotes cellular senescence and lung fibrosis; intranasal recombinant IGFBP2 delivery and transgenic overexpression in aged mice reduced AEC2 senescence markers and SASP factors and ameliorated bleomycin-induced lung fibrosis.","method":"Aged human-IGFBP2 transgenic mice, intranasal recombinant protein delivery, bleomycin fibrosis model, AEC2 isolation with senescence marker quantification","journal":"Cell reports. Medicine","confidence":"High","confidence_rationale":"Tier 2 — transgenic and recombinant protein rescue in vivo, cell-type-specific mechanism, multiple orthogonal readouts","pmids":["36787736"],"is_preprint":false},{"year":2024,"finding":"IGFBP2 induces podocyte apoptosis by binding integrin α5 (ITGA5) and activating FAK phosphorylation, leading to mitochondrial dysfunction (membrane potential loss, ROS increase); ITGA5 knockdown or FAK inhibition attenuated podocyte apoptosis caused by high glucose or IGFBP2 overexpression.","method":"DKD mouse model (STZ), IGFBP2 knockout/knockdown, ITGA5 knockdown, FAK inhibitor, mitochondrial membrane potential assay, ROS measurement","journal":"Apoptosis","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO model with mechanistic validation using integrin/FAK genetic and pharmacological perturbations","pmids":["38796567"],"is_preprint":false},{"year":2024,"finding":"Astrocyte-specific P2Y1R overexpression increases IGFBP2 secretion; secreted IGFBP2 acts as an excitatory signal causing neuronal hyperexcitability and increased neuronal Ca2+ signaling in mouse models of epilepsy and stroke.","method":"Astrocyte-specific P2Y1R transgenic mice, Ca2+ imaging, neuronal excitability recording, IGFBP2 knockdown experiments, epilepsy and stroke disease models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genetic gain-of-function in astrocytes with IGFBP2 as identified downstream effector, functional neuronal readouts, replicated across disease models","pmids":["39117630"],"is_preprint":false},{"year":2022,"finding":"In ovarian high-grade serous carcinoma precursor lesions, IGFBP2 expression is driven by DNA hypomethylation of its proximal enhancer; 5-azacytidine treatment increases IGFBP2 expression, and IGFBP2 knockdown suppresses tubal epithelial cell growth via AKT pathway inactivation.","method":"Spatial transcriptomics, pyrosequencing for methylation, 5-azacytidine treatment, IGFBP2 knockdown with AKT pathway analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — methylation-expression causal link demonstrated with demethylation agent, functional rescue via AKT, spatial transcriptomics for localization","pmids":["36206311"],"is_preprint":false},{"year":2024,"finding":"An omental-specific IGFBP2-high stromal population (mesothelial-mesenchymal transitioning) inhibits human adipose stem and progenitor cell adipogenesis through IGFBP2 secretion, identified by single-cell RNA sequencing and functional co-culture experiments.","method":"Single-cell RNA-seq, bulk RNA-seq of >30 SVF samples, functional co-culture adipogenesis assays with IGFBP2 knockdown","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — single-cell resolution identification + functional co-culture knockdown validation, mechanistic anti-adipogenic role of secreted IGFBP2 established","pmids":["38729152"],"is_preprint":false},{"year":2021,"finding":"COL11A1-mediated ERK activation increases p-SP1, which promotes p65 NF-κB binding to the IGFBP2 promoter, inducing IGFBP2 expression; IGFBP2 in turn activates TGF-β3, which promotes cancer-associated fibroblast (CAF) activation in ovarian cancer, driving IL-6 release, cancer cell proliferation, and invasiveness.","method":"Co-culture experiments, ChIP assay for p65 binding to IGFBP2 promoter, siRNA knockdown, in vivo mouse model with TGF-β3 antibody blockade","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirms direct promoter binding, in vivo rescue with antibody, multiple orthogonal methods","pmids":["34117361"],"is_preprint":false}],"current_model":"IGFBP2 is a multifunctional secreted protein that modulates IGF bioavailability extracellularly by binding IGF-I and IGF-II (cleavable by MMP-9 and MMP-1 to release free IGFs), while also acting intracellularly/in the nucleus via nuclear translocation to transactivate gene promoters (VEGF, IGFBP2 targets), activate EGFR-STAT3 signaling, stabilize cytoplasmic p21, and regulate β-catenin/stemness; at the cell surface it engages integrin receptors (α5β1) to activate FAK/ERK/PI3K-AKT signaling and inactivate PTEN, driving proliferation, invasion, EMT, angiogenesis, and metabolic effects including insulin sensitization and inhibition of adipogenesis in a depot-specific manner."},"narrative":{"teleology":[{"year":2003,"claim":"The discovery that IIp45 binds the RGD-containing C-terminus of IGFBP2 and antagonizes glioma invasion established that IGFBP2 has a direct, IGF-independent pro-invasive function mediated through its integrin-binding domain and linked to NF-κB signaling.","evidence":"Yeast two-hybrid, co-immunoprecipitation, invasion assays, and xenograft models in glioma cells","pmids":["14617774"],"confidence":"High","gaps":["Identity of integrin receptor(s) not determined in this study","Structural basis of IIp45-IGFBP2 interaction unresolved"]},{"year":2005,"claim":"Retroviral IGFBP2 overexpression in chick embryos demonstrated that IGFBP2 inhibits IGF-I/II-mediated chondrocyte proliferation in vivo, establishing its classical role as an extracellular IGF sequestrant in skeletal development.","evidence":"RCAS retroviral overexpression in chick wing, skeletal morphometry, in vitro chondrocyte assays","pmids":["16183342"],"confidence":"High","gaps":["Relative contribution of IGF-I vs IGF-II sequestration not dissected","Whether IGFBP2 also acts via integrins in this skeletal context not tested"]},{"year":2008,"claim":"Demonstrating that MMP-9 cleaves the IGFBP2–IGF-II complex to release bioactive IGF-II revealed a protease-dependent mechanism for local IGF bioavailability regulation, and showed that complex formation itself curtails IGFBP2's autonomous motility-promoting activity.","evidence":"In vitro protease cleavage assay with functional motility and proliferation readouts in astrocytoma cells","pmids":["18563800"],"confidence":"High","gaps":["In vivo relevance of MMP-9 cleavage not confirmed at this point","Cleavage site(s) not precisely mapped"]},{"year":2010,"claim":"Adenoviral IGFBP2 overexpression reversed diabetes across multiple insulin-resistant mouse models, establishing IGFBP2 as a systemic metabolic regulator that improves hepatic insulin sensitivity downstream of leptin signaling.","evidence":"Adenoviral overexpression in ob/ob, Ay/a, DIO, and STZ mice; hyperinsulinemic-euglycemic clamp","pmids":["20074524"],"confidence":"High","gaps":["Receptor and signaling pathway mediating hepatic insulin sensitization not identified","Whether circulating vs. locally produced IGFBP2 is the active species unclear"]},{"year":2011,"claim":"Demonstrating that IGFBP2 localizes to the nucleus and transactivates the VEGF promoter established a paradigm-shifting intracellular/nuclear function beyond its classical secreted IGF-binding role.","evidence":"VEGF promoter luciferase reporter, nuclear fractionation, immunofluorescence, CAM xenograft angiogenesis assay in neuroblastoma cells","pmids":["21750048"],"confidence":"High","gaps":["Nuclear import mechanism (NLS requirements) not defined in this study","DNA-binding domain or cofactors for transactivation not identified"]},{"year":2013,"claim":"Multiple studies converged to show that extracellular IGFBP2 acts through integrin receptors to suppress PTEN, activate PI3K/AKT, and promote survival/chemoresistance, while also functioning as an inhibitor of IGF1R signaling in distinct cellular contexts, revealing context-dependent dual roles.","evidence":"Integrin-blocking and PI3K-inhibitor studies in breast epithelial cells; exogenous IGFBP2 supplementation reversing IGF1R-antibody resistance in rhabdomyosarcoma","pmids":["23515291","24292683"],"confidence":"High","gaps":["How the same protein switches between pro-survival (integrin/PTEN) and IGF-inhibitory modes not resolved","Integrin subunit specificity not yet fully defined"]},{"year":2014,"claim":"IGFBP2 was shown to inhibit adipogenesis in visceral but not subcutaneous adipocytes via its heparin-binding domain and integrin/FAK/PTEN signaling, establishing depot-specific metabolic regulation independent of IGF-I.","evidence":"HBD-mutant IGFBP2, echistatin integrin blockade, dose-response in human adipocytes","pmids":["25370576"],"confidence":"High","gaps":["Heparan sulfate proteoglycan co-receptors mediating depot specificity not identified","In vivo depot-specific effects not directly tested"]},{"year":2015,"claim":"Three parallel advances defined key signaling nodes: IGFBP2 binding to RPTPβ drives PKCζ-mediated vimentin phosphorylation and PTEN inactivation in vascular smooth muscle; IGFBP2 augments nuclear EGFR accumulation and EGFR-STAT3 signaling in glioblastoma; and IGFBP2 with IGF-I coordinately activates AMPK/autophagy required for osteoblast differentiation.","evidence":"Proteomic co-IP and inhibitory peptides in diabetic mice (RPTPβ); nuclear fractionation in GBM cells (EGFR-STAT3); AMPK inhibitors and autophagy readouts in osteoblasts","pmids":["25787077","25893308","26556533"],"confidence":"High","gaps":["Whether RPTPβ and integrin pathways converge or are independent not tested","Nuclear EGFR mechanism relies on correlation in a single lab","AMPK-autophagy link established only in osteoblast lineage"]},{"year":2016,"claim":"IGFBP2 was shown to drive EMT in pancreatic cancer through PI3K/Akt/IKKβ-mediated NF-κB p65 nuclear translocation, with PTEN rescue fully blocking this axis, placing IGFBP2 as an upstream orchestrator of NF-κB-dependent mesenchymal programs.","evidence":"Overexpression/knockdown with PTEN rescue, p65 translocation by immunofluorescence, in vivo metastasis assays","pmids":["27659045"],"confidence":"High","gaps":["Whether IGFBP2's extracellular (integrin) or intracellular pool activates NF-κB not dissected","Epigenetic regulation of IGFBP2 in pancreatic cancer not addressed"]},{"year":2016,"claim":"Site-specific intronic CpG methylation was shown to suppress hepatic IGFBP2 transcription, and this epigenetic silencing precedes obesity and hepatosteatosis, establishing DNA methylation as a causal upstream regulator of IGFBP2 expression with metabolic consequences.","evidence":"In vitro site-specific methylation reporter assay, bisulfite sequencing, mouse dietary model","pmids":["27126637"],"confidence":"High","gaps":["Methyltransferases responsible not identified","Whether demethylation therapy could restore IGFBP2 in vivo not tested"]},{"year":2017,"claim":"MMP-1 was identified as a second protease cleaving IGFBP2-IGF-II complexes, and IGFBP2 was found to exert IGF1R-independent anxiolytic effects by increasing dendritic spine density in brain, broadening its functional repertoire to neuroplasticity.","evidence":"In vitro MMP-1 cleavage of IGFBP2-IGF-II complex with MSC migration assays; in vivo PTSD models with IGF1R antagonist JB1 and dendritic spine analysis","pmids":["29321953","28158790"],"confidence":"Medium","gaps":["MMP-1 cleavage site not mapped","Receptor and signaling mechanism for IGFBP2's neuroplasticity effects unknown","Behavioral studies from single lab"]},{"year":2018,"claim":"Two studies defined critical domain requirements: IGFBP2 interacts with integrin α5β1 to activate FAK/ERK/SP1 and drive CD144/MMP2-dependent vasculogenic mimicry in glioma, and its NLS is required for nuclear translocation of NF-κB p65 and ZEB1-dependent EMT and metastasis.","evidence":"Co-IP for integrin binding, ChIP for SP1 binding to CD144 promoter, orthotopic glioma model; NLS mutant with nuclear fractionation and xenograft metastasis assays in salivary ACC","pmids":["30368528","29885520"],"confidence":"High","gaps":["Structural basis of IGFBP2-integrin α5β1 interaction not resolved","Whether NLS-dependent and integrin-dependent functions are coupled or independent unclear"]},{"year":2020,"claim":"Intracellular IGFBP2 was shown to stabilize cytoplasmic p21 against ubiquitin-mediated degradation, regulate PD-L1 expression through nuclear EGFR/STAT3, drive IL-10-mediated M2 macrophage polarization via STAT3, and modulate β-catenin/Oct4 stemness via integrin-TRIM33, revealing a broad intracellular signaling hub.","evidence":"Co-IP of IGFBP2-p21, ubiquitination assays in keratinocytes; EGFR nuclear fractionation in melanoma; in vivo macrophage depletion in PDAC; RNA immunoprecipitation for β-catenin-Oct4 mRNA in GBM","pmids":["32302288","32120023","33309859","32803659"],"confidence":"Medium","gaps":["p21 stabilization confirmed in one cell type (psoriatic keratinocytes)","β-catenin RNA-binding function is unconventional and lacks independent replication","Relative contribution of secreted vs intracellular IGFBP2 to immune modulation not resolved"]},{"year":2021,"claim":"COL11A1-ERK-SP1-NF-κB was identified as an upstream transcriptional circuit driving IGFBP2 expression, and secreted IGFBP2 activates TGF-β3 to promote cancer-associated fibroblast activation, establishing IGFBP2 as a paracrine mediator of tumor-stroma crosstalk in ovarian cancer.","evidence":"ChIP for p65 binding to IGFBP2 promoter, co-culture experiments, in vivo TGF-β3 antibody blockade","pmids":["34117361"],"confidence":"High","gaps":["Direct IGFBP2-TGF-β3 molecular interaction not characterized","Whether this paracrine axis operates in other tumor types unknown"]},{"year":2022,"claim":"DNA hypomethylation of a proximal enhancer was shown to drive IGFBP2 expression in ovarian cancer precursor lesions, where IGFBP2 sustains tubal epithelial growth via AKT, linking epigenetic derepression to early tumorigenesis.","evidence":"Spatial transcriptomics, pyrosequencing, 5-azacytidine treatment, IGFBP2 knockdown with AKT readout","pmids":["36206311"],"confidence":"High","gaps":["Whether enhancer hypomethylation is a driver or passenger event in serous tumorigenesis not established","AKT-dependent mechanism downstream of IGFBP2 not fully dissected"]},{"year":2023,"claim":"Loss of IGFBP2 in alveolar type 2 cells was shown to promote cellular senescence and lung fibrosis, and intranasal recombinant IGFBP2 or transgenic overexpression attenuated these phenotypes, establishing IGFBP2 as an anti-senescence factor in the lung.","evidence":"Aged IGFBP2 transgenic mice, recombinant protein delivery, bleomycin fibrosis model, AEC2 senescence marker quantification","pmids":["36787736"],"confidence":"High","gaps":["Receptor and signaling pathway mediating anti-senescence effect in AEC2 cells not identified","Whether systemic IGFBP2 levels decline with aging and contribute to fibrosis susceptibility not addressed"]},{"year":2024,"claim":"IGFBP2's integrin α5/FAK axis was extended to podocyte apoptosis via mitochondrial dysfunction in diabetic kidney disease, and astrocyte-derived IGFBP2 was identified as a paracrine excitatory signal increasing neuronal calcium and hyperexcitability in epilepsy and stroke models.","evidence":"IGFBP2 KO in diabetic mice with ITGA5 knockdown and FAK inhibition; astrocyte-specific P2Y1R transgenic mice with IGFBP2 knockdown and neuronal Ca2+ imaging","pmids":["38796567","39117630"],"confidence":"High","gaps":["Whether neuronal excitability effects are integrin-mediated not tested","Specific IGFBP2 receptor on neurons unknown","Whether podocyte effects are IGF-dependent or independent not fully resolved"]},{"year":null,"claim":"Key unresolved questions include: the identity of the neuronal receptor mediating IGFBP2's excitatory effects; the structural basis for IGFBP2's dual extracellular/nuclear functions and how NLS-dependent and integrin-dependent activities are coordinated; the receptor mediating hepatic insulin sensitization; and whether intracellular functions such as p21 stabilization and β-catenin RNA binding generalize beyond single cell-type observations.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of full-length IGFBP2 or its receptor complexes","Hepatic insulin sensitization receptor unknown","Neuronal receptor unknown","Generalizability of intracellular p21 and β-catenin functions untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,8,9,10,11,21]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[8,14]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,15]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,6,9,24]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,8,10,11,14,21,23,25,27]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,4,15]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[17,19]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,6,9,16,24,26]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,10,27]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[16,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[17,24]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,21]}],"complexes":[],"partners":["ITGA5","ITGB1","PTPRB","EGFR","CDKN1A","IIP45","IGF2","IGF1"],"other_free_text":[]},"mechanistic_narrative":"IGFBP2 is a secreted, multifunctional modulator of IGF signaling, integrin-mediated adhesion, and intranuclear transcriptional regulation that governs cell proliferation, survival, metabolism, and tissue remodeling across diverse contexts. Extracellularly, IGFBP2 sequesters IGF-I and IGF-II to inhibit IGF receptor activation—a complex cleavable by MMP-9 and MMP-1 to release free IGFs—and simultaneously engages integrin α5β1 and receptor tyrosine phosphatase β (RTPTβ) to activate FAK/ERK and PI3K/AKT signaling while suppressing PTEN, thereby driving proliferation, invasion, EMT (via NF-κB/ZEB1), vasculogenic mimicry, and depot-specific inhibition of adipogenesis [PMID:30368528, PMID:25787077, PMID:27659045, PMID:25370576, PMID:18563800]. Intracellularly, IGFBP2 translocates to the nucleus via a defined NLS to transactivate the VEGF promoter, promote nuclear EGFR accumulation and EGFR-STAT3 signaling, facilitate NF-κB p65 nuclear translocation, and stabilize cytoplasmic p21 against ubiquitin-dependent degradation, linking it to angiogenesis, immune evasion (PD-L1 upregulation, M2 macrophage polarization via IL-10), and apoptosis resistance [PMID:21750048, PMID:29885520, PMID:32302288, PMID:33309859, PMID:32120023]. Systemically, IGFBP2 functions as a leptin-regulated insulin sensitizer that improves hepatic glucose metabolism, protects alveolar epithelial cells from senescence and fibrosis, and modulates neuronal excitability and dendritic spine plasticity in the brain [PMID:20074524, PMID:36787736, PMID:39117630, PMID:28158790]."},"prefetch_data":{"uniprot":{"accession":"P18065","full_name":"Insulin-like growth factor-binding protein 2","aliases":[],"length_aa":325,"mass_kda":34.8,"function":"Multifunctional protein that plays a critical role in regulating the availability of IGFs such as IGF1 and IGF2 to their receptors and thereby regulates IGF-mediated cellular processes including proliferation, differentiation, and apoptosis in a cell-type specific manner (PubMed:18563800, PubMed:38796567). Functions coordinately with receptor protein tyrosine phosphatase beta/PTPRB and the IGF1 receptor to regulate IGF1-mediated signaling by stimulating the phosphorylation of PTEN leading to its inactivation and AKT1 activation (PubMed:22869525). Plays a positive role in cell migration via interaction with integrin alpha5/ITGA5 through an RGD motif (PubMed:16569642). Additionally, interaction with ITGA5/ITGB1 enhances the adhesion of endothelial progenitor cells to endothelial cells (PubMed:26076738). Upon mitochondrial damage, facilitates apoptosis with ITGA5 of podocytes, and then activates the phosphorylation of focal adhesion kinase (FAK)-mediated mitochondrial injury (PubMed:38796567)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P18065/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IGFBP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IGFBP2","total_profiled":1310},"omim":[{"mim_id":"618157","title":"ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IV; IGHD4","url":"https://www.omim.org/entry/618157"},{"mim_id":"611767","title":"MICRO RNA 126; MIR126","url":"https://www.omim.org/entry/611767"},{"mim_id":"608772","title":"MIGRATION AND INVASION INHIBITORY PROTEIN; MIIP","url":"https://www.omim.org/entry/608772"},{"mim_id":"604705","title":"MER TYROSINE KINASE PROTOONCOGENE; MERTK","url":"https://www.omim.org/entry/604705"},{"mim_id":"601489","title":"INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN, ACID-LABILE SUBUNIT; IGFALS","url":"https://www.omim.org/entry/601489"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"blood vessel","ntpm":1281.4},{"tissue":"pancreas","ntpm":901.3}],"url":"https://www.proteinatlas.org/search/IGFBP2"},"hgnc":{"alias_symbol":[],"prev_symbol":["IBP2"]},"alphafold":{"accession":"P18065","domains":[{"cath_id":"4.10.40.20","chopping":"46-132","consensus_level":"high","plddt":84.4166,"start":46,"end":132},{"cath_id":"4.10.800.10","chopping":"260-320","consensus_level":"medium","plddt":76.3446,"start":260,"end":320}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P18065","model_url":"https://alphafold.ebi.ac.uk/files/AF-P18065-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P18065-F1-predicted_aligned_error_v6.png","plddt_mean":66.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IGFBP2","jax_strain_url":"https://www.jax.org/strain/search?query=IGFBP2"},"sequence":{"accession":"P18065","fasta_url":"https://rest.uniprot.org/uniprotkb/P18065.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P18065/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P18065"}},"corpus_meta":[{"pmid":"7543116","id":"PMC_7543116","title":"Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.","date":"1995","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/7543116","citation_count":392,"is_preprint":false},{"pmid":"20074524","id":"PMC_20074524","title":"Antidiabetic effects of IGFBP2, a leptin-regulated gene.","date":"2010","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20074524","citation_count":237,"is_preprint":false},{"pmid":"1694498","id":"PMC_1694498","title":"Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart.","date":"1990","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1694498","citation_count":185,"is_preprint":false},{"pmid":"10414596","id":"PMC_10414596","title":"Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation.","date":"1999","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/10414596","citation_count":148,"is_preprint":false},{"pmid":"12414507","id":"PMC_12414507","title":"Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12414507","citation_count":148,"is_preprint":false},{"pmid":"31925333","id":"PMC_31925333","title":"IGFBP2: integrative hub of developmental and oncogenic signaling network.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31925333","citation_count":112,"is_preprint":false},{"pmid":"16915540","id":"PMC_16915540","title":"Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.","date":"2006","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/16915540","citation_count":108,"is_preprint":false},{"pmid":"9215312","id":"PMC_9215312","title":"Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor.","date":"1997","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9215312","citation_count":102,"is_preprint":false},{"pmid":"25544066","id":"PMC_25544066","title":"IGFBP-2: The dark horse in metabolism and cancer.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25544066","citation_count":96,"is_preprint":false},{"pmid":"21750048","id":"PMC_21750048","title":"IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21750048","citation_count":95,"is_preprint":false},{"pmid":"1699745","id":"PMC_1699745","title":"Production of insulin-like growth factor binding proteins (IGFBPs) by porcine granulosa cells: identification of IGFBP-2 and -3 and regulation by hormones and growth factors.","date":"1990","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1699745","citation_count":94,"is_preprint":false},{"pmid":"30368528","id":"PMC_30368528","title":"IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30368528","citation_count":94,"is_preprint":false},{"pmid":"27659045","id":"PMC_27659045","title":"IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27659045","citation_count":94,"is_preprint":false},{"pmid":"16183342","id":"PMC_16183342","title":"Role of IGFBP2, IGF-I and IGF-II in regulating long bone growth.","date":"2005","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/16183342","citation_count":93,"is_preprint":false},{"pmid":"27579675","id":"PMC_27579675","title":"Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27579675","citation_count":82,"is_preprint":false},{"pmid":"23233738","id":"PMC_23233738","title":"MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23233738","citation_count":79,"is_preprint":false},{"pmid":"14617774","id":"PMC_14617774","title":"IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14617774","citation_count":76,"is_preprint":false},{"pmid":"26556533","id":"PMC_26556533","title":"IGF-I and IGFBP-2 Stimulate AMPK Activation and Autophagy, Which Are Required for Osteoblast Differentiation.","date":"2015","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26556533","citation_count":75,"is_preprint":false},{"pmid":"8743420","id":"PMC_8743420","title":"Expression of insulin-like growth factor-1 (IGF-1) and IGF-binding protein 2 (IGF-BP2) in the hippocampus following cytotoxic lesion of the dentate gyrus.","date":"1996","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/8743420","citation_count":75,"is_preprint":false},{"pmid":"33309859","id":"PMC_33309859","title":"IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33309859","citation_count":74,"is_preprint":false},{"pmid":"15790698","id":"PMC_15790698","title":"Significant expression of IGFBP2 in breast cancer compared with benign lesions.","date":"2005","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15790698","citation_count":73,"is_preprint":false},{"pmid":"23959956","id":"PMC_23959956","title":"Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.","date":"2013","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23959956","citation_count":71,"is_preprint":false},{"pmid":"25893308","id":"PMC_25893308","title":"IGFBP2 potentiates nuclear EGFR-STAT3 signaling.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25893308","citation_count":71,"is_preprint":false},{"pmid":"11134102","id":"PMC_11134102","title":"Ovarian follicular concentrations of activin, follistatin, inhibin, insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-2 (IGFBP-2), IGFBP-3, and vascular endothelial growth factor in spontaneous menstrual cycles of normal women of advanced reproductive age.","date":"2000","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11134102","citation_count":69,"is_preprint":false},{"pmid":"34117361","id":"PMC_34117361","title":"COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34117361","citation_count":69,"is_preprint":false},{"pmid":"32120023","id":"PMC_32120023","title":"IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32120023","citation_count":66,"is_preprint":false},{"pmid":"27487563","id":"PMC_27487563","title":"The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27487563","citation_count":64,"is_preprint":false},{"pmid":"1699963","id":"PMC_1699963","title":"Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) and IGFBP-2 in human follicular fluid.","date":"1990","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/1699963","citation_count":61,"is_preprint":false},{"pmid":"29721393","id":"PMC_29721393","title":"Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/29721393","citation_count":61,"is_preprint":false},{"pmid":"20515648","id":"PMC_20515648","title":"IGFBP2 promotes glioma tumor stem cell expansion and survival.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20515648","citation_count":60,"is_preprint":false},{"pmid":"36787736","id":"PMC_36787736","title":"Loss of IGFBP2 mediates alveolar type 2 cell senescence and promotes lung fibrosis.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36787736","citation_count":57,"is_preprint":false},{"pmid":"16368782","id":"PMC_16368782","title":"DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.","date":"2005","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16368782","citation_count":57,"is_preprint":false},{"pmid":"1377854","id":"PMC_1377854","title":"Triiodothyronine (T3) stimulates insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-2 production by rat osteoblasts in vitro.","date":"1992","source":"Acta endocrinologica","url":"https://pubmed.ncbi.nlm.nih.gov/1377854","citation_count":55,"is_preprint":false},{"pmid":"24130049","id":"PMC_24130049","title":"IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24130049","citation_count":54,"is_preprint":false},{"pmid":"12478375","id":"PMC_12478375","title":"Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density, in the absence and presence of growth hormone/IGF-I excess in transgenic mice.","date":"2002","source":"Anatomy and embryology","url":"https://pubmed.ncbi.nlm.nih.gov/12478375","citation_count":53,"is_preprint":false},{"pmid":"23515291","id":"PMC_23515291","title":"Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23515291","citation_count":53,"is_preprint":false},{"pmid":"26522454","id":"PMC_26522454","title":"Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential.","date":"2015","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26522454","citation_count":52,"is_preprint":false},{"pmid":"27126637","id":"PMC_27126637","title":"Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27126637","citation_count":51,"is_preprint":false},{"pmid":"19805356","id":"PMC_19805356","title":"IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19805356","citation_count":49,"is_preprint":false},{"pmid":"33416173","id":"PMC_33416173","title":"IGFBP2 in cancer: Pathological role and clinical significance (Review).","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33416173","citation_count":47,"is_preprint":false},{"pmid":"37982669","id":"PMC_37982669","title":"Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits.","date":"2024","source":"The journals of gerontology. Series A, Biological sciences and medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37982669","citation_count":45,"is_preprint":false},{"pmid":"22242132","id":"PMC_22242132","title":"Effects of cord serum insulin, IGF-II, IGFBP-2, IL-6 and cortisol concentrations on human birth weight and length: pilot study.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22242132","citation_count":42,"is_preprint":false},{"pmid":"18946176","id":"PMC_18946176","title":"Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus.","date":"2008","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/18946176","citation_count":42,"is_preprint":false},{"pmid":"17970029","id":"PMC_17970029","title":"Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma.","date":"2007","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17970029","citation_count":41,"is_preprint":false},{"pmid":"16514194","id":"PMC_16514194","title":"The effects of IGF-I on bovine follicle development and IGFBP-2 expression are dose and stage dependent.","date":"2006","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16514194","citation_count":41,"is_preprint":false},{"pmid":"10912521","id":"PMC_10912521","title":"Effects of IGFBP-2 overexpression in vitro and in vivo.","date":"2000","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/10912521","citation_count":40,"is_preprint":false},{"pmid":"25370576","id":"PMC_25370576","title":"IGFBP-2 inhibits adipogenesis and lipogenesis in human visceral, but not subcutaneous, adipocytes.","date":"2014","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/25370576","citation_count":40,"is_preprint":false},{"pmid":"12125963","id":"PMC_12125963","title":"Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness.","date":"2002","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12125963","citation_count":37,"is_preprint":false},{"pmid":"21354155","id":"PMC_21354155","title":"Circulating salmon 41-kDa insulin-like growth factor binding protein (IGFBP) is not IGFBP-3 but an IGFBP-2 subtype.","date":"2011","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21354155","citation_count":37,"is_preprint":false},{"pmid":"21899885","id":"PMC_21899885","title":"High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.","date":"2011","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/21899885","citation_count":36,"is_preprint":false},{"pmid":"37031362","id":"PMC_37031362","title":"High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.","date":"2023","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37031362","citation_count":35,"is_preprint":false},{"pmid":"18550406","id":"PMC_18550406","title":"Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults.","date":"2008","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/18550406","citation_count":35,"is_preprint":false},{"pmid":"31788106","id":"PMC_31788106","title":"Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31788106","citation_count":35,"is_preprint":false},{"pmid":"30347220","id":"PMC_30347220","title":"IGFBP2 promotes neural stem cell maintenance and proliferation differentially associated with glioblastoma subtypes.","date":"2018","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/30347220","citation_count":34,"is_preprint":false},{"pmid":"36206311","id":"PMC_36206311","title":"Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36206311","citation_count":34,"is_preprint":false},{"pmid":"9795362","id":"PMC_9795362","title":"Retinoic acid stimulates IGF binding protein (IGFBP)-6 and depresses IGFBP-2 and IGFBP-4 in SK-N-SH human neuroblastoma cells.","date":"1998","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9795362","citation_count":33,"is_preprint":false},{"pmid":"20730703","id":"PMC_20730703","title":"Modulation of IGFBP2 mRNA expression in white adipose tissue upon aging and obesity.","date":"2010","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/20730703","citation_count":32,"is_preprint":false},{"pmid":"22527168","id":"PMC_22527168","title":"A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.","date":"2012","source":"Cancer causes & control : CCC","url":"https://pubmed.ncbi.nlm.nih.gov/22527168","citation_count":32,"is_preprint":false},{"pmid":"25944386","id":"PMC_25944386","title":"Novel anti IGFBP2 single chain variable fragment inhibits glioma cell migration and invasion.","date":"2015","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25944386","citation_count":30,"is_preprint":false},{"pmid":"32532003","id":"PMC_32532003","title":"Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32532003","citation_count":30,"is_preprint":false},{"pmid":"26348138","id":"PMC_26348138","title":"Roles of miR-278-3p in IBP2 regulation and Bombyx mori cytoplasmic polyhedrosis virus replication.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26348138","citation_count":29,"is_preprint":false},{"pmid":"8944682","id":"PMC_8944682","title":"Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells.","date":"1996","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8944682","citation_count":29,"is_preprint":false},{"pmid":"32302288","id":"PMC_32302288","title":"Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32302288","citation_count":29,"is_preprint":false},{"pmid":"27776273","id":"PMC_27776273","title":"IGFBP-2 and -3 co-ordinately regulate IGF1 induced matrix mineralisation of differentiating human dental pulp cells.","date":"2016","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27776273","citation_count":29,"is_preprint":false},{"pmid":"31560714","id":"PMC_31560714","title":"IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31560714","citation_count":28,"is_preprint":false},{"pmid":"34628696","id":"PMC_34628696","title":"SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34628696","citation_count":28,"is_preprint":false},{"pmid":"38778379","id":"PMC_38778379","title":"Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer.","date":"2024","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/38778379","citation_count":27,"is_preprint":false},{"pmid":"31758655","id":"PMC_31758655","title":"Silencing circular RNA VANGL1 inhibits progression of bladder cancer by regulating miR-1184/IGFBP2 axis.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31758655","citation_count":27,"is_preprint":false},{"pmid":"37982173","id":"PMC_37982173","title":"Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.","date":"2023","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37982173","citation_count":26,"is_preprint":false},{"pmid":"30999686","id":"PMC_30999686","title":"MiR-34b-5p Mediates the Proliferation and Differentiation of Myoblasts by Targeting IGFBP2.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30999686","citation_count":26,"is_preprint":false},{"pmid":"25277046","id":"PMC_25277046","title":"Targeted mass spectrometry analysis of the proteins IGF1, IGF2, IBP2, IBP3 and A2GL by blood protein precipitation.","date":"2014","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/25277046","citation_count":25,"is_preprint":false},{"pmid":"29706932","id":"PMC_29706932","title":"Potential Functions of IGFBP-2 for Ovarian Folliculogenesis and Steroidogenesis.","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29706932","citation_count":25,"is_preprint":false},{"pmid":"8832579","id":"PMC_8832579","title":"The unique endometrial expression and genomic organization of the porcine IGFBP-2 gene.","date":"1996","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8832579","citation_count":25,"is_preprint":false},{"pmid":"29885520","id":"PMC_29885520","title":"IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-κB/ZEB1 signaling pathway.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29885520","citation_count":25,"is_preprint":false},{"pmid":"35569697","id":"PMC_35569697","title":"Metastatic colorectal carcinoma-associated fibroblasts have immunosuppressive properties related to increased IGFBP2 expression.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35569697","citation_count":25,"is_preprint":false},{"pmid":"18563800","id":"PMC_18563800","title":"Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.","date":"2008","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/18563800","citation_count":25,"is_preprint":false},{"pmid":"9675002","id":"PMC_9675002","title":"Estradiol increases relative amounts of insulin-like growth factor binding protein (IGFBP)-3 in serum and expression of IGFBP-2 in anterior pituitaries of ewes.","date":"1998","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/9675002","citation_count":24,"is_preprint":false},{"pmid":"24292683","id":"PMC_24292683","title":"Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24292683","citation_count":24,"is_preprint":false},{"pmid":"31559898","id":"PMC_31559898","title":"BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.","date":"2019","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31559898","citation_count":24,"is_preprint":false},{"pmid":"29500455","id":"PMC_29500455","title":"Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29500455","citation_count":24,"is_preprint":false},{"pmid":"28903396","id":"PMC_28903396","title":"IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28903396","citation_count":23,"is_preprint":false},{"pmid":"30272281","id":"PMC_30272281","title":"Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30272281","citation_count":22,"is_preprint":false},{"pmid":"30873591","id":"PMC_30873591","title":"The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30873591","citation_count":21,"is_preprint":false},{"pmid":"28158790","id":"PMC_28158790","title":"IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity.","date":"2017","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28158790","citation_count":21,"is_preprint":false},{"pmid":"25787077","id":"PMC_25787077","title":"The coordinate cellular response to insulin-like growth factor-I (IGF-I) and insulin-like growth factor-binding protein-2 (IGFBP-2) is regulated through vimentin binding to receptor tyrosine phosphatase β (RPTPβ).","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25787077","citation_count":21,"is_preprint":false},{"pmid":"32380764","id":"PMC_32380764","title":"Associations between IGF1, IGFBP2 and TGFß3 Genes Polymorphisms and Growth Performance of Broiler Chicken Lines.","date":"2020","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/32380764","citation_count":20,"is_preprint":false},{"pmid":"12900778","id":"PMC_12900778","title":"Changes of serum growth factors (IGF-I,-II and IGFBP-2,-3) prior to and after stem cell transplantation in children with acute leukemia.","date":"2003","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/12900778","citation_count":20,"is_preprint":false},{"pmid":"30309683","id":"PMC_30309683","title":"Insulin like growth factor binding protein 2 (IGFBP-2) for risk prediction in patients with severe aortic stenosis undergoing Transcatheter Aortic Valve Implantation (TAVI).","date":"2018","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30309683","citation_count":20,"is_preprint":false},{"pmid":"38918360","id":"PMC_38918360","title":"IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38918360","citation_count":20,"is_preprint":false},{"pmid":"21924226","id":"PMC_21924226","title":"High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21924226","citation_count":19,"is_preprint":false},{"pmid":"31934083","id":"PMC_31934083","title":"IGFBP2 promotes the EMT of colorectal cancer cells by regulating E-cadherin expression.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31934083","citation_count":19,"is_preprint":false},{"pmid":"28977895","id":"PMC_28977895","title":"Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28977895","citation_count":19,"is_preprint":false},{"pmid":"29321953","id":"PMC_29321953","title":"Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex.","date":"2017","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/29321953","citation_count":19,"is_preprint":false},{"pmid":"39117630","id":"PMC_39117630","title":"Disease-relevant upregulation of P2Y1 receptor in astrocytes enhances neuronal excitability via IGFBP2.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39117630","citation_count":18,"is_preprint":false},{"pmid":"33536187","id":"PMC_33536187","title":"ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2.","date":"2021","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33536187","citation_count":18,"is_preprint":false},{"pmid":"30564296","id":"PMC_30564296","title":"IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30564296","citation_count":18,"is_preprint":false},{"pmid":"24548188","id":"PMC_24548188","title":"IGF-I and IGFBP2 in peripheral artery disease: results of a prospective study.","date":"2014","source":"Scandinavian cardiovascular journal : SCJ","url":"https://pubmed.ncbi.nlm.nih.gov/24548188","citation_count":17,"is_preprint":false},{"pmid":"38729152","id":"PMC_38729152","title":"A human omentum-specific mesothelial-like stromal population inhibits adipogenesis through IGFBP2 secretion.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38729152","citation_count":17,"is_preprint":false},{"pmid":"32803659","id":"PMC_32803659","title":"Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma.","date":"2020","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32803659","citation_count":17,"is_preprint":false},{"pmid":"38796567","id":"PMC_38796567","title":"IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin α5/FAK in diabetic kidney disease.","date":"2024","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/38796567","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56011,"output_tokens":6960,"usd":0.136216},"stage2":{"model":"claude-opus-4-6","input_tokens":10719,"output_tokens":4961,"usd":0.26643},"total_usd":0.402646,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"Adenoviral overexpression of IGFBP2 reversed diabetes in insulin-resistant ob/ob, Ay/a, diet-induced obese, and streptozotocin-treated mice; hyperinsulinemic clamp studies showed a 3-fold improvement in hepatic insulin sensitivity, establishing IGFBP2 as a regulator of glucose metabolism downstream of leptin signaling.\",\n      \"method\": \"Adenoviral overexpression in mouse models, hyperinsulinemic clamp studies, liver microarray profiling\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo methods (multiple mouse models + clamp studies), replicated across disease models\",\n      \"pmids\": [\"20074524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IIp45, identified by yeast two-hybrid screening, binds to IGFBP2 through the thyroglobulin-RGD region of IGFBP2's C-terminus, and this interaction antagonizes IGFBP2-stimulated glioma cell invasion both in vitro and in xenograft models, partly by suppressing NF-κB and ICAM-1 expression.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, invasion assays, xenograft model, gene expression profiling\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding confirmed, functional rescue in vitro and in vivo, pathway placement via NF-κB\",\n      \"pmids\": [\"14617774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IGFBP2 overexpression in neuroblastoma cells transactivates the VEGF gene promoter; cell fractionation and immunofluorescence demonstrated nuclear localization of IGFBP2, and transactivation of VEGF promoter required intracellular IGFBP2, leading to proangiogenic activity in chick chorioallantoic membrane xenografts.\",\n      \"method\": \"VEGF promoter luciferase reporter cotransfection, cell fractionation, immunofluorescence, CAM xenograft assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — promoter assay with functional rescue, subcellular fractionation, and in vivo angiogenesis assay in single study\",\n      \"pmids\": [\"21750048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IGFBP2 binding to receptor tyrosine phosphatase β (RPTPβ) together with IGF-I receptor stimulation induces PKCζ-mediated vimentin serine phosphorylation, which drives RPTPβ polymerization, PTEN inactivation, and AKT activation to stimulate vascular smooth muscle cell proliferation during hyperglycemia.\",\n      \"method\": \"Proteomic co-immunoprecipitation, siRNA knockdown, cell-permeable inhibitory peptides, in vivo diabetic mouse model with pharmacological inhibitors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — proteomic identification of binding partner, mechanistic validation with multiple inhibitors, confirmed in vivo in diabetic mice\",\n      \"pmids\": [\"25787077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IGFBP2 augments nuclear accumulation of EGFR and potentiates EGFR-STAT3 signaling, promoting invasion and migration of glioblastoma cells; both exogenous IGFBP2 treatment and intracellular IGFBP2 overexpression activated this nuclear EGFR/STAT3 axis.\",\n      \"method\": \"Nuclear fractionation, invasion/migration assays, siRNA knockdown, TCGA data correlation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — nuclear fractionation and functional assays in single lab, pathway placement via EGFR/STAT3\",\n      \"pmids\": [\"25893308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IGFBP2 drives NF-κB-dependent epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma by inducing nuclear translocation and phosphorylation of the p65 NF-κB subunit through the PI3K/Akt/IKKβ pathway; enforced PTEN expression blocked this pathway and restored epithelial phenotype.\",\n      \"method\": \"Overexpression/knockdown, invasion and metastasis assays in vitro and in vivo, immunofluorescence for p65 translocation, PTEN rescue experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with genetic rescue (PTEN), confirmed in vivo, mechanistic pathway placed\",\n      \"pmids\": [\"27659045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IGFBP2 interacts with integrin α5 and β1 subunits, activating FAK/ERK signaling to increase SP1 transcriptional activity, which binds the CD144 promoter and upregulates CD144 and MMP2, thereby promoting vasculogenic mimicry formation in glioma cells.\",\n      \"method\": \"Co-immunoprecipitation (integrin interaction), luciferase reporter assay, ChIP assay, stable knockdown orthotopic mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — binding partner confirmed by Co-IP, promoter binding by ChIP, in vivo confirmation in orthotopic model\",\n      \"pmids\": [\"30368528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IGF-I and IGFBP-2 coordinately stimulate AMPK activation through their respective receptors in osteoblasts; early AMPK induction drives ULK-1 phosphorylation, beclin-1 and LC3II induction (autophagy), which is required for osteoblast differentiation, while sustained AMPK activation inhibits differentiation.\",\n      \"method\": \"Primary calvarial osteoblast culture, MC-3T3 cells, AMPK inhibitors, constitutively active AMPK expression, autophagy inhibitors, receptor-blocking antibodies\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological and genetic interventions with time-course analysis, receptor-level mechanistic dissection\",\n      \"pmids\": [\"26556533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MMP-9 proteolytically cleaves the IGFBP2-IGFII complex in vitro, releasing free IGFII that enhances astrocytoma cell motility and growth; formation of the IGFBP2-IGFII complex also reduces the pool of free IGFBP2 and thereby inhibits IGFBP2's own cell motility-promoting effect.\",\n      \"method\": \"In vitro protease cleavage assay, cell motility and proliferation assays using LN229 cells, conditioned medium experiments\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic cleavage assay with functional readout, mechanistic dissection of complex vs. free IGFBP2\",\n      \"pmids\": [\"18563800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Exogenous IGFBP2 acting via integrin receptors reduces PTEN levels in breast epithelial cells, protecting them from apoptosis and conferring chemoresistance; this survival function requires functional estrogen receptor-α, and conversely IGFBP2 upregulates ER-α expression via integrin receptors through IGF-IR and PI3K activation in cancer cells.\",\n      \"method\": \"siRNA knockdown, exogenous IGFBP2 treatment, integrin receptor blocking, PI3K inhibitors, ER-α silencing, cell survival assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological perturbations with orthogonal readouts in single study\",\n      \"pmids\": [\"23515291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IGFBP2 inhibits adipogenesis and lipogenesis specifically in visceral (not subcutaneous) human adipocytes via its heparin-binding domain mediating cell-surface association and integrin signaling, leading to FAK phosphorylation and decreased PTEN levels, independent of IGF-I.\",\n      \"method\": \"siRNA knockdown, exogenous IGFBP2 dose-response, HBD-mutant IGFBP2, echistatin (integrin blocker), Western blotting, lipid staining\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological methods with domain-specific mutant, depot-specific mechanistic dissection\",\n      \"pmids\": [\"25370576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IGFBP2 is inhibitory to IGF1R phosphorylation and downstream signaling; in rhabdomyosarcoma, downregulation of IGFBP2 confers resistance to IGF1R antibody therapy, and adding exogenous IGFBP2 potentiates IGF1R antibody activity and reverses resistance in vitro and in vivo.\",\n      \"method\": \"In vivo resistance model, exogenous IGFBP2 supplementation, expression analysis, IGF1R phosphorylation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro causal evidence for IGFBP2's inhibitory role on IGF1R signaling, single lab\",\n      \"pmids\": [\"24292683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hyperglycemia induces IGFBP2 expression in prostate cancer cells via increased acetylation of histones H3 and H4 at the IGFBP2 gene promoter (epigenetic mechanism); elevated IGFBP2 reduces docetaxel-induced apoptosis, and silencing IGFBP2 negates the glucose-mediated survival advantage.\",\n      \"method\": \"siRNA knockdown, chromatin immunoprecipitation (ChIP) for histone acetylation, DNA methylation analysis, ELISA, cell death assay\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrates epigenetic writer mechanism, siRNA rescue confirms causality, single lab\",\n      \"pmids\": [\"23959956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Intronic CpG methylation of IGFBP2 (CpG2605) suppresses its hepatic expression; selective methylation of this site in vitro reduced reporter activity by ~85%, and this epigenetic silencing precedes diet-induced obesity and hepatosteatosis in mice.\",\n      \"method\": \"Bisulfite sequencing, in vitro methylation reporter assay, mouse dietary model with epigenetic profiling\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro site-specific methylation with reporter assay, causal temporal relationship established in vivo\",\n      \"pmids\": [\"27126637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MMP-1 cleaves the IGF-2/IGFBP2 complex, releasing free IGF-2 that facilitates mesenchymal stem cell migration toward tumors; conditioned media from highly migrating MSCs expressing high MMP-1 cleaved the IGF-2/IGFBP2 complex in vitro.\",\n      \"method\": \"In vitro cleavage assay with conditioned media, exogenous recombinant protein addition, migration assays\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — direct in vitro cleavage assay, single lab, moderate mechanistic depth\",\n      \"pmids\": [\"29321953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In salivary adenoid cystic carcinoma, IGFBP2 nuclear localization signal is required for nuclear translocation of NF-κB p65; nuclear IGFBP2 enhances p65-dependent ZEB1 expression to promote EMT; IGFBP2 NLS mutant failed to translocate p65, reduced ZEB1, and abrogated EMT and metastasis in xenograft models.\",\n      \"method\": \"IGFBP2 NLS mutant transfection, nuclear fractionation, invasion assays, xenograft metastasis model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain-specific mutagenesis with in vitro and in vivo validation, pathway placement via NF-κB/ZEB1\",\n      \"pmids\": [\"29885520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IGFBP2 activates STAT3 in pancreatic ductal adenocarcinoma cells to augment IL-10 secretion, which drives tumor-associated macrophage polarization toward an M2 immunosuppressive phenotype, increasing Treg infiltration and impairing antitumor T-cell immunity.\",\n      \"method\": \"In vivo mouse model (macrophage depletion), STAT3 signaling analysis, IL-10 ELISA, flow cytometry for immune cell populations\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo macrophage-dependent validation and mechanistic STAT3/IL-10 link, single lab\",\n      \"pmids\": [\"33309859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Intracellular IGFBP2 stabilizes cytoplasmic p21 by protecting it from ubiquitin-dependent degradation in psoriatic keratinocytes; cytoplasmic p21 in turn inhibits pro-caspase 3 cleavage and JNK phosphorylation to resist apoptosis; silencing IGFBP2 destabilizes p21 and restores apoptosis.\",\n      \"method\": \"IGFBP2 overexpression/silencing in psoriatic keratinocytes, co-immunoprecipitation (IGFBP2-p21 interaction), ubiquitin-mediated degradation assays, caspase and JNK activity assays\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of endogenous interaction, functional rescue with multiple downstream readouts, mechanistically distinct intracellular role defined\",\n      \"pmids\": [\"32302288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IGFBP2 regulates PD-L1 expression in melanoma by facilitating nuclear accumulation of EGFR and activating the EGFR/STAT3 signaling pathway, confirmed both in vitro and in vivo.\",\n      \"method\": \"IGFBP2 knockdown/overexpression, nuclear EGFR fractionation, STAT3 phosphorylation assays, in vivo melanoma models\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — nuclear EGFR mechanism consistent with prior IGFBP2/EGFR/STAT3 papers, single lab, mechanistic readouts\",\n      \"pmids\": [\"32120023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IGFBP2 in glioblastoma cells induces TRIM33 (an E3 ubiquitin ligase) expression via integrin signaling, which depletes nuclear β-catenin; simultaneously, IGFBP2-stabilized cytoplasmic β-catenin binds the 3' UTR of Oct4 RNA, enhancing stemness of glioma cells.\",\n      \"method\": \"RT-PCR, Western blot, shRNA knockdown, RNA immunoprecipitation (RNAIP), luciferase reporter, neurosphere assay\",\n      \"journal\": \"Journal of neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-protein interaction confirmed by RNAIP, mechanistic pathway defined, single lab\",\n      \"pmids\": [\"32803659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IGFBP2 exerts anxiolytic and antistress effects in rat PTSD models via an IGF-1 receptor-independent mechanism (not blocked by IGF1R antagonist JB1 or AMPA receptor antagonist NBQX); IGFBP2 increases mature dendritic spine density in medial prefrontal cortex and hippocampus 24 hours post-dosing, suggesting structural plasticity as the underlying mechanism.\",\n      \"method\": \"Porsolt test, contextual fear conditioning, chronic unpredictable stress model; selective receptor antagonists; dendritic spine morphology analysis in vivo\",\n      \"journal\": \"The international journal of neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of IGF1R-independence with multiple behavioral models, in vivo structural readout, single lab\",\n      \"pmids\": [\"28158790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IGFBP2 overexpression in chick embryo wing by RCAS retroviral vector inhibits IGF-I and IGF-II-mediated chondrocyte proliferation and matrix synthesis, resulting in shortened long bones; IGFBP2 excess also attenuates perichondrium/periosteum proliferation without affecting markers of chondrocyte maturation or osteoblast differentiation.\",\n      \"method\": \"RCAS retroviral overexpression in embryonic chick wing, in vivo skeletal morphometry, in vitro chondrocyte proliferation/matrix synthesis assays with IGF-I/II\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro mechanistic dissection, multiple cellular readouts, defined pathway (inhibition of IGF-mediated proliferation)\",\n      \"pmids\": [\"16183342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MDA-9/syntenin induces HIF-1α via ECM-Src-FAK-Akt signaling, which activates transcription of IGFBP2; secreted IGFBP2 promotes tumor angiogenesis and stimulates endothelial cells to produce and secrete VEGF-A.\",\n      \"method\": \"Gain/loss-of-function experiments, tube formation assay, CAM assay, xenograft tumor model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic manipulation with in vitro and in vivo angiogenesis assays, pathway placed downstream of HIF-1α, single lab\",\n      \"pmids\": [\"23233738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of IGFBP2 in alveolar type 2 (AEC2) cells promotes cellular senescence and lung fibrosis; intranasal recombinant IGFBP2 delivery and transgenic overexpression in aged mice reduced AEC2 senescence markers and SASP factors and ameliorated bleomycin-induced lung fibrosis.\",\n      \"method\": \"Aged human-IGFBP2 transgenic mice, intranasal recombinant protein delivery, bleomycin fibrosis model, AEC2 isolation with senescence marker quantification\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic and recombinant protein rescue in vivo, cell-type-specific mechanism, multiple orthogonal readouts\",\n      \"pmids\": [\"36787736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IGFBP2 induces podocyte apoptosis by binding integrin α5 (ITGA5) and activating FAK phosphorylation, leading to mitochondrial dysfunction (membrane potential loss, ROS increase); ITGA5 knockdown or FAK inhibition attenuated podocyte apoptosis caused by high glucose or IGFBP2 overexpression.\",\n      \"method\": \"DKD mouse model (STZ), IGFBP2 knockout/knockdown, ITGA5 knockdown, FAK inhibitor, mitochondrial membrane potential assay, ROS measurement\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO model with mechanistic validation using integrin/FAK genetic and pharmacological perturbations\",\n      \"pmids\": [\"38796567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Astrocyte-specific P2Y1R overexpression increases IGFBP2 secretion; secreted IGFBP2 acts as an excitatory signal causing neuronal hyperexcitability and increased neuronal Ca2+ signaling in mouse models of epilepsy and stroke.\",\n      \"method\": \"Astrocyte-specific P2Y1R transgenic mice, Ca2+ imaging, neuronal excitability recording, IGFBP2 knockdown experiments, epilepsy and stroke disease models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic gain-of-function in astrocytes with IGFBP2 as identified downstream effector, functional neuronal readouts, replicated across disease models\",\n      \"pmids\": [\"39117630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In ovarian high-grade serous carcinoma precursor lesions, IGFBP2 expression is driven by DNA hypomethylation of its proximal enhancer; 5-azacytidine treatment increases IGFBP2 expression, and IGFBP2 knockdown suppresses tubal epithelial cell growth via AKT pathway inactivation.\",\n      \"method\": \"Spatial transcriptomics, pyrosequencing for methylation, 5-azacytidine treatment, IGFBP2 knockdown with AKT pathway analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — methylation-expression causal link demonstrated with demethylation agent, functional rescue via AKT, spatial transcriptomics for localization\",\n      \"pmids\": [\"36206311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"An omental-specific IGFBP2-high stromal population (mesothelial-mesenchymal transitioning) inhibits human adipose stem and progenitor cell adipogenesis through IGFBP2 secretion, identified by single-cell RNA sequencing and functional co-culture experiments.\",\n      \"method\": \"Single-cell RNA-seq, bulk RNA-seq of >30 SVF samples, functional co-culture adipogenesis assays with IGFBP2 knockdown\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — single-cell resolution identification + functional co-culture knockdown validation, mechanistic anti-adipogenic role of secreted IGFBP2 established\",\n      \"pmids\": [\"38729152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"COL11A1-mediated ERK activation increases p-SP1, which promotes p65 NF-κB binding to the IGFBP2 promoter, inducing IGFBP2 expression; IGFBP2 in turn activates TGF-β3, which promotes cancer-associated fibroblast (CAF) activation in ovarian cancer, driving IL-6 release, cancer cell proliferation, and invasiveness.\",\n      \"method\": \"Co-culture experiments, ChIP assay for p65 binding to IGFBP2 promoter, siRNA knockdown, in vivo mouse model with TGF-β3 antibody blockade\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct promoter binding, in vivo rescue with antibody, multiple orthogonal methods\",\n      \"pmids\": [\"34117361\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IGFBP2 is a multifunctional secreted protein that modulates IGF bioavailability extracellularly by binding IGF-I and IGF-II (cleavable by MMP-9 and MMP-1 to release free IGFs), while also acting intracellularly/in the nucleus via nuclear translocation to transactivate gene promoters (VEGF, IGFBP2 targets), activate EGFR-STAT3 signaling, stabilize cytoplasmic p21, and regulate β-catenin/stemness; at the cell surface it engages integrin receptors (α5β1) to activate FAK/ERK/PI3K-AKT signaling and inactivate PTEN, driving proliferation, invasion, EMT, angiogenesis, and metabolic effects including insulin sensitization and inhibition of adipogenesis in a depot-specific manner.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IGFBP2 is a secreted, multifunctional modulator of IGF signaling, integrin-mediated adhesion, and intranuclear transcriptional regulation that governs cell proliferation, survival, metabolism, and tissue remodeling across diverse contexts. Extracellularly, IGFBP2 sequesters IGF-I and IGF-II to inhibit IGF receptor activation—a complex cleavable by MMP-9 and MMP-1 to release free IGFs—and simultaneously engages integrin α5β1 and receptor tyrosine phosphatase β (RTPTβ) to activate FAK/ERK and PI3K/AKT signaling while suppressing PTEN, thereby driving proliferation, invasion, EMT (via NF-κB/ZEB1), vasculogenic mimicry, and depot-specific inhibition of adipogenesis [PMID:30368528, PMID:25787077, PMID:27659045, PMID:25370576, PMID:18563800]. Intracellularly, IGFBP2 translocates to the nucleus via a defined NLS to transactivate the VEGF promoter, promote nuclear EGFR accumulation and EGFR-STAT3 signaling, facilitate NF-κB p65 nuclear translocation, and stabilize cytoplasmic p21 against ubiquitin-dependent degradation, linking it to angiogenesis, immune evasion (PD-L1 upregulation, M2 macrophage polarization via IL-10), and apoptosis resistance [PMID:21750048, PMID:29885520, PMID:32302288, PMID:33309859, PMID:32120023]. Systemically, IGFBP2 functions as a leptin-regulated insulin sensitizer that improves hepatic glucose metabolism, protects alveolar epithelial cells from senescence and fibrosis, and modulates neuronal excitability and dendritic spine plasticity in the brain [PMID:20074524, PMID:36787736, PMID:39117630, PMID:28158790].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"The discovery that IIp45 binds the RGD-containing C-terminus of IGFBP2 and antagonizes glioma invasion established that IGFBP2 has a direct, IGF-independent pro-invasive function mediated through its integrin-binding domain and linked to NF-κB signaling.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, invasion assays, and xenograft models in glioma cells\",\n      \"pmids\": [\"14617774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of integrin receptor(s) not determined in this study\", \"Structural basis of IIp45-IGFBP2 interaction unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Retroviral IGFBP2 overexpression in chick embryos demonstrated that IGFBP2 inhibits IGF-I/II-mediated chondrocyte proliferation in vivo, establishing its classical role as an extracellular IGF sequestrant in skeletal development.\",\n      \"evidence\": \"RCAS retroviral overexpression in chick wing, skeletal morphometry, in vitro chondrocyte assays\",\n      \"pmids\": [\"16183342\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of IGF-I vs IGF-II sequestration not dissected\", \"Whether IGFBP2 also acts via integrins in this skeletal context not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that MMP-9 cleaves the IGFBP2–IGF-II complex to release bioactive IGF-II revealed a protease-dependent mechanism for local IGF bioavailability regulation, and showed that complex formation itself curtails IGFBP2's autonomous motility-promoting activity.\",\n      \"evidence\": \"In vitro protease cleavage assay with functional motility and proliferation readouts in astrocytoma cells\",\n      \"pmids\": [\"18563800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of MMP-9 cleavage not confirmed at this point\", \"Cleavage site(s) not precisely mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Adenoviral IGFBP2 overexpression reversed diabetes across multiple insulin-resistant mouse models, establishing IGFBP2 as a systemic metabolic regulator that improves hepatic insulin sensitivity downstream of leptin signaling.\",\n      \"evidence\": \"Adenoviral overexpression in ob/ob, Ay/a, DIO, and STZ mice; hyperinsulinemic-euglycemic clamp\",\n      \"pmids\": [\"20074524\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and signaling pathway mediating hepatic insulin sensitization not identified\", \"Whether circulating vs. locally produced IGFBP2 is the active species unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that IGFBP2 localizes to the nucleus and transactivates the VEGF promoter established a paradigm-shifting intracellular/nuclear function beyond its classical secreted IGF-binding role.\",\n      \"evidence\": \"VEGF promoter luciferase reporter, nuclear fractionation, immunofluorescence, CAM xenograft angiogenesis assay in neuroblastoma cells\",\n      \"pmids\": [\"21750048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear import mechanism (NLS requirements) not defined in this study\", \"DNA-binding domain or cofactors for transactivation not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Multiple studies converged to show that extracellular IGFBP2 acts through integrin receptors to suppress PTEN, activate PI3K/AKT, and promote survival/chemoresistance, while also functioning as an inhibitor of IGF1R signaling in distinct cellular contexts, revealing context-dependent dual roles.\",\n      \"evidence\": \"Integrin-blocking and PI3K-inhibitor studies in breast epithelial cells; exogenous IGFBP2 supplementation reversing IGF1R-antibody resistance in rhabdomyosarcoma\",\n      \"pmids\": [\"23515291\", \"24292683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same protein switches between pro-survival (integrin/PTEN) and IGF-inhibitory modes not resolved\", \"Integrin subunit specificity not yet fully defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"IGFBP2 was shown to inhibit adipogenesis in visceral but not subcutaneous adipocytes via its heparin-binding domain and integrin/FAK/PTEN signaling, establishing depot-specific metabolic regulation independent of IGF-I.\",\n      \"evidence\": \"HBD-mutant IGFBP2, echistatin integrin blockade, dose-response in human adipocytes\",\n      \"pmids\": [\"25370576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heparan sulfate proteoglycan co-receptors mediating depot specificity not identified\", \"In vivo depot-specific effects not directly tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Three parallel advances defined key signaling nodes: IGFBP2 binding to RPTPβ drives PKCζ-mediated vimentin phosphorylation and PTEN inactivation in vascular smooth muscle; IGFBP2 augments nuclear EGFR accumulation and EGFR-STAT3 signaling in glioblastoma; and IGFBP2 with IGF-I coordinately activates AMPK/autophagy required for osteoblast differentiation.\",\n      \"evidence\": \"Proteomic co-IP and inhibitory peptides in diabetic mice (RPTPβ); nuclear fractionation in GBM cells (EGFR-STAT3); AMPK inhibitors and autophagy readouts in osteoblasts\",\n      \"pmids\": [\"25787077\", \"25893308\", \"26556533\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RPTPβ and integrin pathways converge or are independent not tested\", \"Nuclear EGFR mechanism relies on correlation in a single lab\", \"AMPK-autophagy link established only in osteoblast lineage\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"IGFBP2 was shown to drive EMT in pancreatic cancer through PI3K/Akt/IKKβ-mediated NF-κB p65 nuclear translocation, with PTEN rescue fully blocking this axis, placing IGFBP2 as an upstream orchestrator of NF-κB-dependent mesenchymal programs.\",\n      \"evidence\": \"Overexpression/knockdown with PTEN rescue, p65 translocation by immunofluorescence, in vivo metastasis assays\",\n      \"pmids\": [\"27659045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IGFBP2's extracellular (integrin) or intracellular pool activates NF-κB not dissected\", \"Epigenetic regulation of IGFBP2 in pancreatic cancer not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Site-specific intronic CpG methylation was shown to suppress hepatic IGFBP2 transcription, and this epigenetic silencing precedes obesity and hepatosteatosis, establishing DNA methylation as a causal upstream regulator of IGFBP2 expression with metabolic consequences.\",\n      \"evidence\": \"In vitro site-specific methylation reporter assay, bisulfite sequencing, mouse dietary model\",\n      \"pmids\": [\"27126637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methyltransferases responsible not identified\", \"Whether demethylation therapy could restore IGFBP2 in vivo not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"MMP-1 was identified as a second protease cleaving IGFBP2-IGF-II complexes, and IGFBP2 was found to exert IGF1R-independent anxiolytic effects by increasing dendritic spine density in brain, broadening its functional repertoire to neuroplasticity.\",\n      \"evidence\": \"In vitro MMP-1 cleavage of IGFBP2-IGF-II complex with MSC migration assays; in vivo PTSD models with IGF1R antagonist JB1 and dendritic spine analysis\",\n      \"pmids\": [\"29321953\", \"28158790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MMP-1 cleavage site not mapped\", \"Receptor and signaling mechanism for IGFBP2's neuroplasticity effects unknown\", \"Behavioral studies from single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Two studies defined critical domain requirements: IGFBP2 interacts with integrin α5β1 to activate FAK/ERK/SP1 and drive CD144/MMP2-dependent vasculogenic mimicry in glioma, and its NLS is required for nuclear translocation of NF-κB p65 and ZEB1-dependent EMT and metastasis.\",\n      \"evidence\": \"Co-IP for integrin binding, ChIP for SP1 binding to CD144 promoter, orthotopic glioma model; NLS mutant with nuclear fractionation and xenograft metastasis assays in salivary ACC\",\n      \"pmids\": [\"30368528\", \"29885520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of IGFBP2-integrin α5β1 interaction not resolved\", \"Whether NLS-dependent and integrin-dependent functions are coupled or independent unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Intracellular IGFBP2 was shown to stabilize cytoplasmic p21 against ubiquitin-mediated degradation, regulate PD-L1 expression through nuclear EGFR/STAT3, drive IL-10-mediated M2 macrophage polarization via STAT3, and modulate β-catenin/Oct4 stemness via integrin-TRIM33, revealing a broad intracellular signaling hub.\",\n      \"evidence\": \"Co-IP of IGFBP2-p21, ubiquitination assays in keratinocytes; EGFR nuclear fractionation in melanoma; in vivo macrophage depletion in PDAC; RNA immunoprecipitation for β-catenin-Oct4 mRNA in GBM\",\n      \"pmids\": [\"32302288\", \"32120023\", \"33309859\", \"32803659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"p21 stabilization confirmed in one cell type (psoriatic keratinocytes)\", \"β-catenin RNA-binding function is unconventional and lacks independent replication\", \"Relative contribution of secreted vs intracellular IGFBP2 to immune modulation not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"COL11A1-ERK-SP1-NF-κB was identified as an upstream transcriptional circuit driving IGFBP2 expression, and secreted IGFBP2 activates TGF-β3 to promote cancer-associated fibroblast activation, establishing IGFBP2 as a paracrine mediator of tumor-stroma crosstalk in ovarian cancer.\",\n      \"evidence\": \"ChIP for p65 binding to IGFBP2 promoter, co-culture experiments, in vivo TGF-β3 antibody blockade\",\n      \"pmids\": [\"34117361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IGFBP2-TGF-β3 molecular interaction not characterized\", \"Whether this paracrine axis operates in other tumor types unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"DNA hypomethylation of a proximal enhancer was shown to drive IGFBP2 expression in ovarian cancer precursor lesions, where IGFBP2 sustains tubal epithelial growth via AKT, linking epigenetic derepression to early tumorigenesis.\",\n      \"evidence\": \"Spatial transcriptomics, pyrosequencing, 5-azacytidine treatment, IGFBP2 knockdown with AKT readout\",\n      \"pmids\": [\"36206311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether enhancer hypomethylation is a driver or passenger event in serous tumorigenesis not established\", \"AKT-dependent mechanism downstream of IGFBP2 not fully dissected\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Loss of IGFBP2 in alveolar type 2 cells was shown to promote cellular senescence and lung fibrosis, and intranasal recombinant IGFBP2 or transgenic overexpression attenuated these phenotypes, establishing IGFBP2 as an anti-senescence factor in the lung.\",\n      \"evidence\": \"Aged IGFBP2 transgenic mice, recombinant protein delivery, bleomycin fibrosis model, AEC2 senescence marker quantification\",\n      \"pmids\": [\"36787736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and signaling pathway mediating anti-senescence effect in AEC2 cells not identified\", \"Whether systemic IGFBP2 levels decline with aging and contribute to fibrosis susceptibility not addressed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"IGFBP2's integrin α5/FAK axis was extended to podocyte apoptosis via mitochondrial dysfunction in diabetic kidney disease, and astrocyte-derived IGFBP2 was identified as a paracrine excitatory signal increasing neuronal calcium and hyperexcitability in epilepsy and stroke models.\",\n      \"evidence\": \"IGFBP2 KO in diabetic mice with ITGA5 knockdown and FAK inhibition; astrocyte-specific P2Y1R transgenic mice with IGFBP2 knockdown and neuronal Ca2+ imaging\",\n      \"pmids\": [\"38796567\", \"39117630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether neuronal excitability effects are integrin-mediated not tested\", \"Specific IGFBP2 receptor on neurons unknown\", \"Whether podocyte effects are IGF-dependent or independent not fully resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the identity of the neuronal receptor mediating IGFBP2's excitatory effects; the structural basis for IGFBP2's dual extracellular/nuclear functions and how NLS-dependent and integrin-dependent activities are coordinated; the receptor mediating hepatic insulin sensitization; and whether intracellular functions such as p21 stabilization and β-catenin RNA binding generalize beyond single cell-type observations.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of full-length IGFBP2 or its receptor complexes\", \"Hepatic insulin sensitization receptor unknown\", \"Neuronal receptor unknown\", \"Generalizability of intracellular p21 and β-catenin functions untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 8, 9, 10, 11, 21]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [8, 14]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 15]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 6, 9, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 8, 10, 11, 14, 21, 23, 25, 27]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 4, 15]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [17, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 6, 9, 16, 24, 26]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 10, 27]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [16, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [17, 24]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ITGA5\",\n      \"ITGB1\",\n      \"PTPRB\",\n      \"EGFR\",\n      \"CDKN1A\",\n      \"IIp45\",\n      \"IGF2\",\n      \"IGF1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}